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INTRODUCTION
Kidney transplantation (KT) is the treatment of choice for
most patients with end-stage renal disease (ESRD). The sur-
vival of patients who undergo KT has improved considerably
over the past three decades. Although successful kidney trans-
plantation is accompanied by a 10- to 20-yr increase in life
expectancy (1), the survival of kidney transplant recipients
is significantly shortened by atherosclerotic cardiovascular
disease, which accounts for 40% to 55% of all deaths in these
patients (2). 
It is well established that angiographically-determined
coronary atherosclerosis scored by the modified Gensini index
(MGI) has a high predictive value for mortality in both the
general population (3) and ESRD patients (4). Moreover, in
kidney transplant patients, coronary atherosclerosis is con-
sidered to be influenced by a wide range of more complicat-
ed conditions. Despite this, correlates of the degree of coro-
nary atherosclerosis in long-term kidney transplant patients
have not been documented. Therefore, the aim of this study
was to identify clinical and echocardiographic parameters
independently associated with the angiographically-deter-
mined severity of coronary atherosclerosis, as determined by
MGI, in long-term kidney transplant patients.
MATERIALS AND METHODS
Study design and patients
We retrospectively analyzed 52 kidney transplant patients
with functioning grafts who underwent both elective coro-
nary angiography and echocardiography at the same hospi-
talization due to suspected coronary artery disease at Sever-
ance Hospital, Yonsei University Health System, Seoul, Korea
between July 1997 and July 2007 under approval from the
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Correlates of the Severity of Coronary Atherosclerosis in Long-term
Kidney Transplant Patients
Coronary artery disease remains the leading cause of early death and graft loss in
renal transplant patients. The aim of this study was to identify clinical and echocar-
diographic parameters independently associated with the angiographically-deter-
mined severity of coronary atherosclerosis in long-term kidney transplant patients.
Fifty-two kidney transplant recipients who underwent elective coronary angiogra-
phy were reviewed retrospectively. Angiographic severity was evaluated using the
modified Gensini index (MGI). The mean age at coronary angiography was 52.5±
7.9 yr with a mean prior transplant duration of 118.1±58.8 months. Pearson cor-
relation analysis demonstrated a positive correlation of MGI with transplant dura-
tion before coronary angiography and chronic allograft nephropathy, whereas an
inverse correlation was demonstrated with ejection fraction and statin use. On sub-
sequent multivariate linear regression analysis, transplant duration before coronary
angiography, statin use, and ejection fraction were independently associated with
the severity of coronary atherosclerosis in long-term kidney transplant patients. In
summary, our study demonstrates that statin use, ejection fraction, and transplant
duration before coronary angiography are independent parameters associated with
the severity of coronary atherosclerosis in long-term kidney transplant patients. Fur-
ther investigation is required to reduce the atherosclerotic burden in kidney trans-
plant patients.
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institutional review board (IRB number 4-2009-0383). Sub-
jects were excluded if they had a past history of coronary artery
bypass graft surgery, coronary angioplasty, carotid artery sur-
gery, or a cerebrovascular accident.
Immunosuppressive regimes
Most patients were treated with a triple regime of a cal-
cineurin inhibitor (cyclosporine or tacrolimus) plus a purine
synthesis inhibitor (azathioprine or mycophenolate mofetil)
and prednisolone.
Clinical and laboratory parameters
We reviewed the clinical characteristics (age, gender, smok-
ing habits, type of primary renal disease, history of preexist-
ing hypertension, history of biopsy-proven acute rejection or
chronic allograft nephropathy, pre- or post-transplantation
diabetes mellitus, the duration and type of dialysis prior to
transplantation, and concurrent medications) of all patients
prior to coronary angiography. Anthropometric parameters,
such as body mass index, blood pressure, and biochemical
indices (hemoglobin, total protein, albumin, calcium, phos-
phorus, lipid profile, blood urea nitrogen, creatinine, C-reac-
tive protein [CRP] level, and presence or absence of protein-
uria on dipstick test) were recorded as the values document-
ed at the hospitalization for coronary angiography. Since blood
pressure and low-density lipoprotein (LDL) cholesterol were
considered established cardiovascular risk factors in general
population, they were analyzed as both continuous (mean arte-
rial pressure and serum LDL cholesterol level) and categori-
cal variables (moderate blood pressure control group, blood
pressure <140/90 mmHg vs. intensive blood pressure con-
trol group, blood pressure <130/80; moderate LDL choles-
terol lowering group, LDL cholesterol <100 mg/dL vs. inten-
sive LDL cholesterol lowering group, LDL cholesterol <70
mg/dL), respectively. Renal function was estimated using the
abbreviated Modification of Diet in Renal Disease (MDRD)
study equation (5). 
Assessment of severity of coronary atherosclerosis and
echocardiographic studies
The participants in the study were referred to our institu-
tion for elective coronary angiography due to suspected coro-
nary artery disease (complaints of chest discomfort, high risk
profiles, or abnormal test results). The coronary arteries were
cannulated using the Judkins technique (6) with five F cathe-
ters and recorded on cine film. At least six standardized pro-
jections of the left coronary artery and two of the right coro-
nary artery were obtained routinely. Using the results of the
coronary artery cine film, the severity of coronary atheroscle-
rosis was evaluated numerically by MGI. This index assigns a
heavier weight to the more severe luminal narrowings. Weights
are also assigned to each segment depending on vessel size
and importance; segments serving larger regions of myocardi-
um are more heavily weighted (3, 7). Echocardiographic ex-
aminations and measurements of cardiac indices were per-
formed at the hospitalization for coronary angiography using
M-mode and two-dimensional ultrasonography with color
Doppler, as recommended by the American Society of Echocar-
diography (8).
Statistical analysis
Data are expressed as mean±SD. Pearson correlation anal-
yses were performed to analyze the association of clinical and
echocardiographic parameters with the extent of coronary
atherosclerosis scored by MGI. Subsequently, stepwise mul-
tivariate linear regression analysis was performed to deter-
mine the factors independently associated with the severity
of coronary atherosclerosis. P values of less than 0.05 were
considered statistically significant. Because CRP levels were
not normally distributed in this study, these data were nor-
malized by base-10 log transformation before entering regres-
sion analyses. All statistical analyses were performed using
SPSS for Windows software, version 12.0 (SPSS Inc, Chica-
go, IL, USA).
RESULTS
Patient characteristics
The clinical characteristics of the 52 patients are listed in
Table 1. The mean age at coronary angiography was 52.5±
7.9 yr, with a mean prior transplant duration of 118.1±58.8
months. Of the 52 patients, 42 (80.8%) were male. The mean
age at KT was 42.8±8.1 yr, with a mean prior dialysis dura-
tion of 26.1±31.8 months. Thirty-six (69.2%) of the pati-
ents had been on hemodialysis prior to transplantation. MGI
values ranged from 0 to 344 (median, 48; mean, 71.5±65.8). 
Univariate analysis of factors correlated with modified
Gensini index 
Univariate Pearson correlation analyses of the associations
of clinical and echocardiographic left ventricular indices with
the extent of coronary atherosclerosis as scored by MGI are
shown in Table 2. Chronic allograft nephropathy (r=0.278,
P=0.046) was significantly related to higher MGI, whereas
statin use was significantly related to lower MGI (r=-0.353,
P=0.010). There were also significantly positive correlations
of MGI with diastolic left ventricular internal dimension (r=
0.414, P=0.002), systolic left ventricular internal dimension
(r=0.474, P<0.001), and transplant duration before coronary
angiography (r=0.355, P=0.010). In contrast, there were sig-
nificantly negative correlations of MGI with ejection fraction
708 H.-W. Kim, S.-W. Kang, H.Y. Lee, et al.
(r=-0.446, P=0.001) and fractional shortening (r=-0.369,
P=0.007).
Multivariate analysis of factors independently associated
with modified Gensini index
Stepwise multivariate linear regression analysis, Adjusted
for age at coronary angiography, gender, diabetes mellitus,
history of chronic allograft nephropathy, renal function mea-
sured by MDRD equation, and duration of dialysis before
KT, revealed that statin use, ejection fraction, and transplant
duration before coronary angiography were independently
correlated with the severity of coronary atherosclerosis scored
by MGI (r2=0.386) (Table 3).
DISCUSSION
A number of factors contribute to cardiovascular atheroscle-
rosis in kidney transplant patients. These fall into the cate-
gories of traditional factors identified by the Framingham
study, including age, male gender, diabetes, hypertension,
hyperlipidemia, and smoking (9), and non-traditional fac-
tors, including renal insufficiency, dialysis treatment (10),
and transplant state per se along with the treatment course
(11, 12). 
While decreased renal function has been shown to be not
only a well established risk factor for adverse cardiovascular
outcomes in both the general population (13) and kidney
transplant patients (14), but also an independent correlate
of angiographically-determined coronary atherosclerosis in
the transplant-naïve general population (15), our study show-
ed that renal allograft function at coronary angiography was
not correlated with the severity of coronary atherosclerosis.
However, biopsy-proven chronic allograft nephropathy was
shown to be significantly correlated with the extent of coro-
nary atherosclerosis. In support of this finding, advanced gly-
cation end products and oxidative stress, a major culprit in
atherosclerosis, have been reported to be increased in chron-
ic allograft nephropathy, and this cannot be explained solely
*Characteristics are expressed as mean±SD or number (%).
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; BSA, body surface area; ESRD, end-stage renal disease; GFR,
glomerular filtration rate; KT, kidney transplantation; LDL, low-density lipoprotein; MDRD, Modification of Diet in Renal Disease.
Age (yr)
At KT 42.8±8.1
At coronary angiography 52.5±7.9
Gender, female (%) 10 (19.2)
Causes of ESRD
Diabetes mellitus (%) 4 (7.7)
Hypertension and others (%) 35 (67.3)
Glomerulonephritis (%) 13 (25.0)
Duration of dialysis before KT (months) 26.1±31.8
Dialysis modality before KT
Pre-emptive transplant 4 (7.7)
Hemodialysis 36 (69.2)
Peritoneal dialysis 7 (13.5)
Combined modality 5 (9.6)
Transplant duration before coronary angiography 118.1±58.8
(months)
Co-morbidities
Hypertension (%) 51 (98.1)
Diabetes mellitus (%) 31 (59.6)
Post-transplantation Diabetes mellitus (%) 27 (51.9)
Smoking (%) 18 (34.6)
History of acute allograft rejection (%) 16 (30.8)
History of chronic allograft nephropathy (%) 19 (36.5)
Medication
Aspirin (%) 10 (19.2)
ACEI/ARB (%) 17 (32.7)
Statin (%) 18 (34.6)
Maintenance corticosteroid dose (mg/day) 11.2±2.1
Maintenance cyclosporin dose (mg/day) 163.9±45.5
Modified Gensini index 71.5±68.5
Mean arterial pressure at angiography (mmHg) 95.1±14.0
Moderate blood pressure control group 36 (69.2)
Intensive blood pressure control group 15 (28.8)
Body mass index (kg/m2) 22.7±2.7
Biochemical parameters
Hemoglobin (g/dL) 11.5±1.9
Ca×P product (mg2/dL2) 31.5±7.4
Albumin (g/dL) 3.6±0.4
Total cholesterol (mg/dL) 201.2±48.9
LDL cholesterol (mg/dL) 130.6±44.2
Moderate LDL cholesterol lowering group 11 (21.2)
Intensive LDL cholesterol lowering group 6 (11.5)
C-reactive protein (mg/dL) 11.6±36.9
GFR by MDRD method (mL/min/1.73 m2) 54.6±19.9
Proteinuria on dipstick test (%) 12 (23.1)
Left ventricular hypertrophy (%) 37 (71.2)
Concentric hypertrophy (%) 22 (42.3)
Eccentric hypertrophy (%) 15 (28.9)
Echocardiographic parameters at coronary 
angiography
Septal wall thickness (mm) 11.4±2.1
Diastolic left ventricular internal dimension (mm) 51.4±7.7
Systolic left ventricular internal dimension (mm) 35.0±9.0
Posterior wall thickness (mm) 11.2±1.9
Relative wall thickness 0.44±0.10
Ejection fraction (%) 61.4±14.4
Fractional shortening (%) 32.6±8.3
Left ventricular mass (g) 229.6±74.7
Left ventricular mass/BSA (g/m2) 135.6±37.4
Left ventricular mass/height2.7 (g/m2.7) 58.8±16.7
Table 1. Patient characteristics*
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by the decline in renal function (16). Rather, this was pos-
tulated to be mediated by overt and subclinical inflamma-
tory rejection episodes. Statin use showed an independent
negative correlation with MGI. Consistent with this, Holdaas
et al. revealed that renal transplant patients who received flu-
vastatin had a 21% reduction in major adverse cardiac events
and a 29% reduction in cardiac death or definite non-fatal
myocardial infarction (17). It has also been reported that renal
transplant patients receiving pravastatin had less severe extra-
coronary atherosclerosis in the carotid and femoral arteries
than the control group, as measured by intima-media thick-
ness (18). In contrast, either absolute serum LDL cholesterol
levels or degree of lipid lowering were not correlates of coro-
nary arthrosclerosis. Taken together, this can be explained by
previously reported vessel-protective effects of statin even in
the absence of lipid lowering (19). While hypertension was
another traditional cardiovascular risk factor in non-trans-
plant patients, a consistent relationship between hyperten-
sion and posttransplant vascular event in transplant patients
has failed to be established (20, 21). In line with this, we did
*Adjusted for age at coronary angiography, gender, diabetes mellitus, history of chronic allograft nephropathy, renal function measured by MDRD equa-
tion, and duration of dialysis before KT.
KT, kidney transplantation; MDRD, Modification of Diet in Renal Disease.
Unstandardized coefficient
Variables
Standardized
coefficients (b) t P valuesStd. ErrorB
Statin use -41.203 15.571 -0.301 -2.646 0.011
Ejection fraction (%) -1.753 0.523 -0.383 -3.354 0.002
Transplant duration before coronary 0.340 0.127 0.304 2.676 0.010
angiography (months)
Table 3. Stepwise multivariate linear regression analysis of factors significantly associated with modified Gensini indices (r 2=0.386*)
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; BSA, body surface area; CRP, C-reactive protein; GFR, glomeru-
lar filtration rate; KT, kidney transplantation; LDL, low-density lipoprotein; MDRD, Modification of Diet in Renal Disease.
Age (yr)
At KT -0.242 0.083
At coronary angiography -0.032 0.819
Gender, male 0.223 0.113
Duration of dialysis before KT (months) -0.140 0.323
Transplant duration before coronary 0.355 0.010
angiography (months)
Co-morbidities
Hypertension 0.102 0.471
Diabetes mellitus -0.043 0.760
Post-transplantation Diabetes mellitus 0.022 0.875
Smoking 0.023 0.869
History of acute allograft rejection -0.048 0.738
History of chronic allograft nephropathy 0.278 0.046
Medication
Aspirin -0.081 0.568
ACEI/ARB -2.000 0.155
Statin -0.353 0.010
Maintenance corticosteroid dose (mg/day) 0.017 0.903
Maintenance cyclosporin dose (mg/day) -0.199 0.184
Body mass index (kg/m2) 0.027 0.851
Mean arterial pressure at angiography (mmHg) -0.239 0.089
Moderate blood pressure control group 0.262 0.060
Intensive blood pressure control group -0.014 0.923
Biochemical parameters
Hemoglobin (g/dL) -0.035 0.807
Ca×P product (mg2/dL2) -0.032 0.824
Albumin (g/dL) -0.184 0.191
Total cholesterol (mg/dL) -0.135 0.339
LDL cholesterol (mg/dL) 0.065 0.660
Moderate LDL cholesterol lowering group -0.022 0.881
Intensive LDL cholesterol lowering group 0.046 0.751
Log CRP 0.237 0.244
GFR by MDRD method (mL/min/1.73 m2) -0.147 0.299
Proteinuria on dipstick test 0.200 0.155
Left ventricular hypertrophy 0.216 0.124
Concentric hypertrophy -0.020 0.886
Eccentric hypertrophy 0.238 0.089
Echocardiographic parameters at coronary 
angiography
Septal wall thickness (mm) -0.160 0.257
Diastolic left ventricular internal dimension (mm) 0.414 0.002
Systolic left ventricular internal dimension (mm) 0.474 <0.001
Posterior wall thickness (mm) -0.089 0.529
Relative wall thickness -0.251 0.073
Ejection fraction (%) -0.446 0.001
Fractional shortening (%) -0.369 0.007
Left ventricular mass (g) 0.172 0.223
Left ventricular mass/BSA (g/m2) 0.172 0.270
Left ventricular mass/height2.7 (g/m2.7) 0.121 0.392
Table 2. Pearson correlations of clinical parameters with modified Gensini indices at coronary angiography
Variables
Modified Gensini index
Correlation 
coefficient (b)
P
values
Variables
Modified Gensini index
Correlation 
coefficient (b)
P
values
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not find a significant correlation between mean arterial pres-
sure or degree of blood pressure control and the severity of
coronary atherosclerosis.
Although early clinical reports on the association between
the degree of coronary arterial narrowing and left ventricu-
lar dysfunction are inconsistent (22), it has been recognized
that myocardial infarcts result in alterations in ventricular
architecture involving both the infarcted and non infarcted
zones through ventricular remodeling (23) and in about 20%
of patients following myocardial infarction, left ventricular
dilatation tends to be progressive and is associated with a dete-
rioration of global left ventricular function (24). Moreover,
Anversa et al. demonstrated experimentally that a fixed reduc-
tion in luminal diameter of the coronary arteries clearly leads
to deterioration in ventricular pump performance (25). Con-
sistent with this, we showed that left ventricular systolic dys-
function determined by echocardiography was independent-
ly associated with coronary atherosclerosis. Notably in our
study, coronary atherosclerosis was more exclusively associ-
ated with the degree of left ventricular systolic dysfunction
accompanied by left ventricular cavity dilatation than left
ventricular mass in long-term kidney transplant patients.
Kidney transplant patients are exposed to an increased athe-
rosclerotic burden at each separate stage of renal disease and
with each treatment modality. As previously mentioned, renal
insufficiency with resulting retention of uremic solutes is
considered a pathologic condition characterized by acceler-
ated atherosclerosis, which tends to be more accentuated in
patients undergoing maintenance dialysis (10). It has been
demonstrated that dialysis duration is a correlate of coronary
calcification (26) and an independent predictor of cardiovas-
cular disease and mortality in stable renal transplant recipi-
ents (27). Moreover, restoration of renal function by trans-
plantation is only capable of modulating or slightly improv-
ing, but not completely stabilizing, the metabolic abnormal-
ities associated with uremia. While one study using spiral
computed tomography demonstrated that KT stabilized coro-
nary artery calcification in ESRD patients during the first
15-20 months after KT (26), multiple sources of evidence
indicate that the kidney transplant state itself is implicated
in the etiology of several pro-atherosclerotic changes. Serum
levels of homocysteine were significantly increased in renal
transplant patients compared to both healthy individuals and
transplant-naïve patients with comparable degrees of renal
failure (28). In addition, serum levels of advanced glycation
end-products were higher in renal transplant patients than
healthy subjects (29). Furthermore, it has been reported that
after KT, the inflammatory cytokines, tumor necrosis factor-
a and interleukin-6, after initially decreasing at 6 months,
increased significantly from 12 months to 18 months. These
results may be explained by a low-grade subclinical immune
response against the allograft or occult infection (30). Con-
sistent with this, we found that in long-term renal transplant
patients, transplant duration before coronary angiography
was a more powerful independent predictor of the severity
of coronary atherosclerosis than duration of dialysis before
KT or age at coronary angiography. 
This study has some limitations, including the small num-
ber of participants and a retrospective single center cross-sec-
tional design; however, to the best of our knowledge, this is
the first report to explore the relationship between non-inva-
sive clinical parameters and the angiographically-determined
severity of coronary atherosclerosis in long-term kidney trans-
plant patients. The lack of available reports may be due to
the small number of angiographic studies performed in kid-
ney transplant patients, which may be related to fear of the
potential damage that can be caused by angiography or con-
trast nephropathy.
In summary, our study demonstrates that statin use, ejec-
tion fraction, and transplant duration before coronary angiog-
raphy are independent parameters associated with the sever-
ity of coronary atherosclerosis in long-term kidney transplant
patients. Further investigation is required to reduce the athe-
rosclerotic burden in kidney transplant patients. 
REFERENCES
1. Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa
LY, Held PJ, Port FK. Comparison of mortality in all patients on
dialysis, patients on dialysis awaiting transplantation, and recipients
of a first cadaveric transplant. N Engl J Med 1999; 341: 1725-30.
2. Fazelzadeh A, Mehdizadeh AR, Ostovan MA, Raiss-Jalali GA. Pre-
dictors of cardiovascular events and associated mortality of kidney
transplant recipients. Transplant Proc 2006; 38: 509-11.
3. Ringqvist I, Fisher LD, Mock M, Davis KB, Wedel H, Chaitman
BR, Passamani E, Russell RO Jr, Alderman EL, Kouchoukas NT,
Kaiser GC, Ryan TJ, Killip T, Fray D. Prognostic value of angio-
graphic indices of coronary artery disease from the Coronary Artery
Surgery Study (CASS). J Clin Invest 1983; 71: 1854-66.
4. Joki N, Hase H, Takahashi Y, Ishikawa H, Nakamura R, Imamura
Y, Tanaka Y, Saijyo T, Fukazawa M, Inishi Y, Nakamura M, Yam-
aguchi T. Angiographical severity of coronary atherosclerosis pre-
dicts death in the first year of hemodialysis. Int Urol Nephrol 2003;
35: 289-97.
5. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more
accurate method to estimate glomerular filtration rate from serum
creatinine: a new prediction equation. Modification of Diet in Renal
Disease Study Group. Ann Intern Med 1999; 130: 461-70.
6. Judkins MP. Selective coronary arteriography. I. A percutaneous
transfemoral technic. Radiology 1967; 89: 815-24.
7. Gensini GG. A more meaningful scoring system for determining the
severity of coronary heart disease. Am J Cardiol 1983; 51: 606.
8. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pel-
likka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon
SD, Spencer KT, Sutton MS, Stewart WJ. Recommendations for
chamber quantification: a report from the American Society of Echo-
cardiography’s Guidelines and Standards Committee and the Cham-
Coronary Atherosclerosis in Long-term KT Patients 711
ber Quantification Writing Group, developed in conjunction with the
European Association of Echocardiography, a branch of the European
Society of Cardiology. J Am Soc Echocardiogr 2005; 18: 1440-63.
9. Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ische-
mic heart disease risk after renal transplantation. J Am Soc Nephrol
2000; 11: 1735-43.
10. Horl WH, Cohen JJ, Harrington JT, Madias NE, Zusman CJ. Athero-
sclerosis and uremic retention solutes. Kidney Int 2004; 66: 1719-31.
11. Kasiske BL. Risk factors for accelerated atherosclerosis in renal
transplant recipients. Am J Med 1988; 84: 985-92.
12. Chueh SC, Kahan BD. Dyslipidemia in renal transplant recipients
treated with a sirolimus and cyclosporine-based immunosuppres-
sive regimen: incidence, risk factors, progression, and prognosis.
Transplantation 2003; 76: 375-82.
13. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Grif-
fith JL, Salem DN, Levey AS, Sarnak MJ. Chronic kidney disease
as a risk factor for cardiovascular disease and all-cause mortality:
a pooled analysis of community-based studies. J Am Soc Nephrol
2004; 15: 1307-15.
14. Meier-Kriesche HU, Baliga R, Kaplan B. Decreased renal function
is a strong risk factor for cardiovascular death after renal transplan-
tation. Transplantation 2003; 75: 1291-5.
15. Na KY, Kim CW, Song YR, Chin HJ, Chae DW. The association
between kidney function, coronary artery disease, and clinical out-
come in patients undergoing coronary angiography. J Korean Med
Sci 2009; 24 (Suppl 1): S87-94.
16. Raj DS, Lim G, Levi M, Qualls C, Jain SK. Advanced glycation end
products and oxidative stress are increased in chronic allograft ne-
phropathy. Am J Kidney Dis 2004; 43: 154-60.
17. Holdaas H, Fellstrom B, Cole E, Nyberg G, Olsson AG, Pedersen
TR, Madsen S, Gronhagen-Riska C, Neumayer HH, Maes B, Ambuhl
P, Hartmann A, Staffler B, Jardine AG. Long-term cardiac outcomes
in renal transplant recipients receiving fluvastatin: the ALERT exten-
sion study. Am J Transplant 2005; 5: 2929-36.
18. Cofan F, Gilabert R, Zambon D, Nunez I, Ros E, Cofan M, Camp-
istol JM, Bru C, Oppenheimer F. Effect of pravastatin treatment on
the evolution of extracoronary atherosclerosis in renal transplant
patients. Transplant Proc 2002; 34: 384-8.
19. Wilson SH, Simari RD, Best PJ, Peterson TE, Lerman LO, Aviram
M, Nath KA, Holmes DR Jr, Lerman A. Simvastatin preserves coro-
nary endothelial function in hypercholesterolemia in the absence of
lipid lowering. Arterioscler Thromb Vasc Biol 2001; 21: 122-8.
20. Florijn KW, Chang PC, van der Woude FJ, van Bockel JH, van Saase
JL. Long-term cardiovascular morbidity and mortality in autosomal
dominant polycystic kidney disease patients after renal transplanta-
tion. Transplantation 1994; 57: 73-81.
21. Kasiske BL, Guijarro C, Massy ZA, Wiederkehr MR, Ma JZ. Car-
diovascular disease after renal transplantation. J Am Soc Nephrol
1996; 7: 158-65.
22. Roeske WR, Savage RM, O’Rourke RA, Bloor CM. Clinicopatho-
logic correlations in patients after myocardial infarction. Circula-
tion 1981; 63: 36-45.
23. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial
infarction. Experimental observations and clinical implications. Circu-
lation 1990; 81: 1161-72.
24. Gaudron P, Eilles C, Kugler I, Ertl G. Progressive left ventricular
dysfunction and remodeling after myocardial infarction. Potential
mechanisms and early predictors. Circulation 1993; 87: 755-63.
25. Anversa P, Zhang X, Li P, Capasso JM. Chronic coronary artery
constriction leads to moderate myocyte loss and left ventricular dys-
function and failure in rats. J Clin Invest 1992; 89: 618-29.
26. Moe SM, O’Neill KD, Fineberg N, Persohn S, Ahmed S, Garrett P,
Meyer CA. Assessment of vascular calcification in ESRD patients
using spiral CT. Nephrol Dial Transplant 2003; 18: 1152-8.
27. Ducloux D, Motte G, Challier B, Gibey R, Chalopin JM. Serum total
homocysteine and cardiovascular disease occurrence in chronic,
stable renal transplant recipients: a prospective study. J Am Soc
Nephrol 2000; 11: 134-7.
28. Arnadottir M, Hultberg B, Vladov V, Nilsson-Ehle P, Thysell H.
Hyperhomocysteinemia in cyclosporine-treated renal transplant
recipients. Transplantation 1996; 61: 509-12.
29. Franke S, Muller A, Sommer M, Busch M, Kientsch-Engel R, Stein
G. Serum levels of total homocysteine, homocysteine metabolites
and of advanced glycation end-products (AGEs) in patients after
renal transplantation. Clin Nephrol 2003; 59: 88-97.
30. Cueto-Manzano AM, Morales-Buenrostro LE, Gonzalez-Espinoza
L, Gonzalez-Tableros N, Martin-del-Campo F, Correa-Rotter R,
Valera I, Alberu J. Markers of inflammation before and after renal
transplantation. Transplantation 2005; 80: 47-51.
